Mantle cell lymphoma · 4 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Lenalidomide and Rituximab (R2) Variant #10 | — | R 86 746 | 35d | — | ~8.5 mo | — | — | 1 |
BFR, then allo HSCT Variant #01 | — | R 67 343 | — | — | — | — | — | — |
Fludarabine, Busulfan, Cyclophosphamide, then allo HSCT Variant #01 | — | R 16 788 | — | — | — | — | — | — |
V-BEAM Variant #01 Partial | — | R 6 993 | — | — | — | — | — | — |
4 of 4 regimens shown